{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091745","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.045600+00:00","generated_at":"2026-05-31T12:19:25.278341+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ARS Pharma Q2 net loss $12.5M; neffy PDUFA Oct 2; cash $218.7M","bullets":["Cash, equivalents and short-term investments $218.7M as of June 30, 2024, providing at least three years of operating runway.","Net loss $12.5M vs $17.4M in Q2 2023; R&D $6.9M, G&A $8.9M.","neffy NDA under FDA review; draft physician labeling received; PDUFA target action date October 2, 2024.","EURneffy received CHMP positive opinion; formal EU marketing authorization expected Q3 2024.","Phase 2b outpatient study of neffy for urticaria on track to start dosing in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091745","json":"https://secwatch.observer/filing/0000950170-24-091745.json","markdown":"https://secwatch.observer/filing/0000950170-24-091745.md","text":"https://secwatch.observer/filing/0000950170-24-091745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000095017024091745/0000950170-24-091745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000095017024091745/spry-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:19:25.278341+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}